
Opinion|Videos|April 7, 2025
Current Practices and Initial Treatment Considerations for Patients With cGVHD
Author(s)Nelson Chao, MD, MBA
A panelist discusses how steroid therapy remains the cornerstone of acute graft-vs-host disease (GVHD) treatment, with treatment protocols typically starting with prednisone at doses ranging from 1 to 2 mg/kg/day depending on disease severity, though optimal dosing strategies continue to be refined through clinical research.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please elaborate on steroid therapy for GVHD.
- What are your thoughts on the prednisone dosing for this patient?
- Are there any additional considerations to monitor and treat for (ie, supportive care)?
- When do you consider other treatment modalities beyond steroid therapy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















